Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation. The company has also received orphan drug and Fast Track designations for lenabasum in systemic sclerosis and dermatomyositis, underscoring regulatory recognition of its potential to address conditions with limited treatment options. Corbus continues to explore additional indications for its pipeline operations, seeking partnerships and collaborations to support late-stage development and eventual commercialization.

Founded in 2006 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals primarily serves patients in North America and Europe through its clinical trial network. Under the leadership of President and Chief Executive Officer Kenneth T. Leonard and Chief Financial Officer Robert J. Conway, the company remains focused on advancing innovative therapies for complex inflammatory diseases and positioning itself as a leader in resolution pharmacology.

Key Stats

• Today's Range: $9.75 to $10.17
• 50-Day Range: $6.90 to $10.47
• 52-Week Range: $4.64 to $56.93
• Volume: 57,623 shs
• Average Volume: 96,261 shs
• Market Capitalization: $120.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.00
• Consensus Rating: Buy

Corbus Pharmaceuticals Stock Analysis - MarketRank™

Corbus Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 153rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Corbus Pharmaceuticals has a consensus price target of $49.00, representing about 397.0% upside from its current price of $9.86.

Amount of Analyst Coverage

Corbus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.23) to ($6.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corbus Pharmaceuticals is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corbus Pharmaceuticals is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Corbus Pharmaceuticals has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.30% of the float of Corbus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Corbus Pharmaceuticals has recently decreased by 2.42%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corbus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Corbus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.65

Percentage of Shares Shorted

11.30% of the float of Corbus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Corbus Pharmaceuticals has recently decreased by 2.42%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Corbus Pharmaceuticals has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Corbus Pharmaceuticals this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 5 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Corbus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRBP Stock Analysis - Frequently Asked Questions

How have CRBP shares performed this year?

Corbus Pharmaceuticals' stock was trading at $11.80 on January 1st, 2025. Since then, CRBP stock has decreased by 16.4% and is now trading at $9.86.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.11.

Who are Corbus Pharmaceuticals' major shareholders?

Top institutional shareholders of Corbus Pharmaceuticals include Exome Asset Management LLC (2.26%), Armistice Capital LLC (1.57%), Atle Fund Management AB (1.43%) and Geode Capital Management LLC (1.09%). Insiders that own company stock include Yuval Cohen, Sean F Moran, Anne Altmeyer and John Kenneth Jenkins.
View institutional ownership trends.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRBP
• CIK: 1595097
• Web: www.corbuspharma.com
• Phone: (617) 963-0100
• Fax: 617-663-6085
• Employees: 40
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Corbus Pharmaceuticals: $49.00
• High Price Target: $74.00
• Low Price Target: $28.00
• Potential Upside/Downside: +397.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.65%
• Return on Assets: -39.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.21
• Quick Ratio: 9.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.69 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 12,260,000
• Free Float: 11,814,000
• Market Cap: $120.88 million
• Optionable: Optionable
• Beta: 3.08